



### **Notification of Recalculated 340B Prices**

BioMarin Pharmaceutical Inc. (“BioMarin”) has recently recalculated 340B ceiling prices for the NDCs references below for the time period of Q4 2020 – Q1 2021.

<b>NDC</b>	<b>Product Description</b>
<b>68135-0020-01</b>	<b>NAGLAZYME 1MG/ML INJ</b>

BioMarin has used chargeback data to identify covered entities that may be eligible for a potential refund based on the recalculated 340B ceiling prices and to identify potential payment amounts to affected 340B covered entities. BioMarin will contact any 340B covered entity that may be owed a refund. BioMarin is not seeking repayment where a 340B covered entity paid a lower price than the recalculated 340B ceiling price. In the meantime, if a Covered Entity would like to contact BioMarin regarding this notice, please email the company at [340B@bmrn.com](mailto:340B@bmrn.com).

BioMarin has asked the Health Resources and Services Administration (“HRSA”) to post this Notice on the HRSA’s public website to ensure transparency to all 340B covered entities regarding the ceiling price recalculations for all NDCs identified above and to offer a refund to any of the 340B covered entities that may have purchased the above NDC during the relevant time periods.